Exelixis EXEL has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from ...

Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under ...

It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in ...

The reported number represents a change of -6.1% year over year. Revenue- Royalty Receipts- Growth Products- Cabometyx/Cometriq : $16.74 million compared to the $16.79 million average estimate ...

Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

The collective assessment of analysts points to an estimated 'Revenues- Net product- COMETRIQ' of $4.24 million. The estimate points to a change of -33.3% from the year-ago quarter. The consensus ...

Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under ...

The estimate indicates a change of +2.1% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Revenues- Net product- COMETRIQ' of $4.24 million. The estimate ...